Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer

S. M. Pontier; L. Huck; D. E. White; J. Rayment; V. Sanguin-Gendreau; B. Hennessy; D. Zuo; R. St-Arnaud; G. B. Mills; S. Dedhar; C. J. Marshall; W. J. Muller

doi:10.1038/onc.2010.86

Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer

S. M. Pontier, L. Huck, D. E. White, J. Rayment, V. Sanguin-Gendreau, B. Hennessy, D. Zuo, R. St-Arnaud, G. B. Mills, S. Dedhar, C. J. Marshall, W. J. Muller

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.

Original language	English (US)
Pages (from-to)	3374-3385
Number of pages	12
Journal	Oncogene
Volume	29
Issue number	23
DOIs	https://doi.org/10.1038/onc.2010.86
State	Published - Jun 10 2010
Externally published	Yes

Keywords

ErbB2
Integrin-linked kinase
Mammary tumorigenesis

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/onc.2010.86

Fingerprint Dive into the research topics of 'Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer'. Together they form a unique fingerprint.

Cite this

Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression : Implications for human breast cancer. / Pontier, S. M.; Huck, L.; White, D. E.; Rayment, J.; Sanguin-Gendreau, V.; Hennessy, B.; Zuo, D.; St-Arnaud, R.; Mills, G. B.; Dedhar, S.; Marshall, C. J.; Muller, W. J.

In: Oncogene, Vol. 29, No. 23, 10.06.2010, p. 3374-3385.

Research output: Contribution to journal › Article › peer-review

@article{eb0715a009a648c480c9dfa7f97efa07,

title = "Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: Implications for human breast cancer",

abstract = "Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.",

keywords = "ErbB2, Integrin-linked kinase, Mammary tumorigenesis",

author = "Pontier, {S. M.} and L. Huck and White, {D. E.} and J. Rayment and V. Sanguin-Gendreau and B. Hennessy and D. Zuo and R. St-Arnaud and Mills, {G. B.} and S. Dedhar and Marshall, {C. J.} and Muller, {W. J.}",

year = "2010",

month = jun,

day = "10",

doi = "10.1038/onc.2010.86",

language = "English (US)",

volume = "29",

pages = "3374--3385",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "23",

}

TY - JOUR

T1 - Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression

T2 - Implications for human breast cancer

AU - Pontier, S. M.

AU - Huck, L.

AU - White, D. E.

AU - Rayment, J.

AU - Sanguin-Gendreau, V.

AU - Hennessy, B.

AU - Zuo, D.

AU - St-Arnaud, R.

AU - Mills, G. B.

AU - Dedhar, S.

AU - Marshall, C. J.

AU - Muller, W. J.

PY - 2010/6/10

Y1 - 2010/6/10

N2 - Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.

AB - Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction.

KW - ErbB2

KW - Integrin-linked kinase

KW - Mammary tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=77953477155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953477155&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.86

DO - 10.1038/onc.2010.86

M3 - Article

C2 - 20305688

AN - SCOPUS:77953477155

VL - 29

SP - 3374

EP - 3385

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 23

ER -